苯妥英酶诱导治疗奈玛特韦/利托那韦致他克莫司超治疗水平:病例系列与讨论
本文报告5例实体器官移植受者因门诊使用奈玛特韦/利托那韦导致他克莫司水平超治疗(>59 ng/mL)并出现毒性症状的病例。所有患者停用奈玛特韦/利托那韦和他克莫司,口服苯妥英(200-400 mg/日)2-4天,他克莫司水平降至合适水平后恢复用药。提示苯妥英酶诱导可能是处理该药物相互作用所致他克莫司水平过高的有用策略。
要点
- 实体器官移植受者使用奈玛特韦/利托那韦时需警惕他克莫司毒性。
- 他克莫司水平>59 ng/mL时,可考虑停用他克莫司并口服苯妥英200-400 mg/日2-4天。
- 他克莫司水平降至合适水平后可重新启用他克莫司。
核心结论
- 使用苯妥英进行代谢诱导可能是处理奈玛特韦/利托那韦联用所致他克莫司超治疗水平的有用策略。
研究设计与样本
- 病例系列,纳入5例成人实体器官移植受者,因门诊使用奈玛特韦/利托那韦后出现他克莫司水平超治疗并伴毒性症状。
主要发现
- 5例患者他克莫司浓度均大于59 ng/mL,并出现他克莫司毒性体征和症状。
- 所有患者停用奈玛特韦/利托那韦和他克莫司,并口服苯妥英200-400 mg/日,持续2至4天。
- 他克莫司水平降至合适水平后恢复他克莫司治疗。
关键数值与推荐
- 他克莫司超治疗水平定义为大于59 ng/mL。
- 苯妥英口服剂量为200-400 mg/日,疗程2至4天。
临床怎么用
- 对于使用奈玛特韦/利托那韦后出现他克莫司水平超治疗且伴毒性症状的实体器官移植受者,可考虑停用他克莫司并短期使用苯妥英酶诱导。
- 他克莫司水平降至合适水平后应重新启用他克莫司。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nirmatrelvir/ritonavir is one of few options for outpatient treatment of COVID-19, but its use has been limited in transplant recipients due to significant drug interactions with immunosuppressants. Tacrolimus toxicity is possible when the drug is coadministered with nirmatrelvir/ritonavir and may require urgent reduction of tacrolimus levels. This case series describes the use of phenytoin for enzyme induction in 5 adult solid organ transplant recipients with supratherapeutic tacrolimus levels resulting from coadministration with nirmatrelvir/ritonavir. SUMMARY: Solid organ transplant recipients are at high risk for complications related to COVID-19. Outpatient treatment options are limited, and therapeutic drug monitoring is complex in patients requiring quarantine. The 5 solid organ transplant recipients described herein were initiated on nirmatrelvir/ritonavir in the outpatient setting and subsequently presented with supratherapeutic tacrolimus concentrations greater than 59 ng/mL and developed signs and symptoms of tacrolimus toxicity. In all patients, nirmatrelvir/ritonavir and tacrolimus were discontinued, and oral phenytoin (200-400 mg/day) was given for 2 to 4 days. Tacrolimus was resumed once tacrolimus levels decreased to appropriate levels. CONCLUSION: These observations demonstrate that metabolism induction using phenytoin may be a useful strategy in the setting of supratherapeutic tacrolimus levels resulting from concomitant administration with nirmatrelvir/ritonavir.
引用
- Marsh J, Logan AT, Bilgili EP, et al. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion. Am J Health Syst Pharm. 2024. PMID: 38347740. doi:10.1093/ajhp/zxae032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。